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Introduction
The extract from the leaves of Ginkgo biloba (GBE) plays a
role in cellular physiological and pharmacological functions.
GBE is used for treating impaired brain functions in elderly and
peripheral arterial occlusive diseases (1,2). Pharmacological
experiments have recently demonstrated that GBE (i) increases
cerebral blood flow, decreases viscosity and antagonizes platelet
activating factor receptors (3,4); (ii) increases tolerance for
anoxia by preventing the decrease in ATP level (5); (iii) improves
neurotransmitter disturbances (6,7); and (iv) prevents cell damage
induced by free radicals (8–10).
GBE contains many chemical constituents. The major
constituents are terpenes such as bilobalide, ginkgolide A,
ginkgolide B and ginkgolide C, and flavonoids such as
quercetin, kaempferol and isorhamnetin (6,11). In the cardio-
vascular system, GBE does not affect heart rate and contractil-
ity, but produces a concentration-dependent increase in coronary
flow (12,13). In our previous experiments, however, we have
found that GBE prolongs the action potential duration (APD),
whereas bilobalide, a main constituent, shortens the APD in
cardiomyocytes (14). The alterations of the action potential con-
figurations clinically would lead to the pathophysiological
changes in the electrocardiogram (ECG). In addition, Tamago
et al. (15) have shown that ginkgolide B is a PAF-antagonist and
acts on the APD, consistent with our results.
The mechanisms of the therapeutic effectiveness of GBE
are expected to be extremely complex, because of the large
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derivative work this must be clearly indicated.number of its constituent substances (6,8). Unknown mecha-
nisms of these constituents for the ionic channel currents still
remain. The aim of the present experiments was to examine,
by use of a patch-clamp technique, how these constituents of
GBE, other than bilobalide, affect the action potentials and the
underlying ionic currents. In addition, the cardiac electrophar-
macological actions of each constituent were compared.
Materials and Methods
All experiments were carried out according to the guidelines
laid down by the Nara Medical University Animal Welfare com-
mittee, and also under the terms of the Declaration of Helsinki.
Cell Preparation
Cells were prepared from tissue taken from the ventricle muscle
of guinea pig hearts, using methods similar to those described
previously (14,16). Under sodium pentobarbital (30 mg/kg, i.p.)
anesthesia, the chest was opened and the aorta was cannulated
in situ. The heart was dissected out and perfused with normal
Tyrode solution on the Langendorff apparatus. After a washout
of blood, the heart was perfused with Ca2 -free Tyrode solution,
and spontaneous beating ceased. Then, the perfusate was
switched to low-Ca2  (30–60  M) Tyrode solution containing
0.4 mg/ml collagenase (Type I, Sigma Chemical, St Louis, MO)
for about 20 min. The heart was washed out by high-K  and
low-Cl solution (KB solution), and was dissected with scissors.
The temperature of all solutions was maintained at 36 C.
Current- and Voltage-clamp Experiments
Current-clamp and whole-cell voltage-clamp recordings were
performed using an Axopatch patch-clamp amplifier (Axon
Instruments, Burlingame, CA) and standard techniques. Patch
pipettes from borosilicate glass capillaries were fabricated
using a two-stage puller, and had a resistance of 5–7 M . The
series resistance error was  3–7 mV, and no compensation was
used. The liquid junction potential between the pipette solution
and the external solution ( 10 mV) was corrected for all mem-
brane potential recordings. Experiments were carried out at a
temperature of 36.5 C. The data were stored and analyzed on
an IBM-AT microcomputer, using the PCLAMP analysis pro-
gram (Axon Instruments). Current traces were filtered using a
cut-off frequency of 1 kHz for plotting. The ICa was measured
as the difference between the peak current and the zero current,
and the IK1 was the difference between the current at the end of
a 1-s test pulse and the zero current. The IK was measured at the
peak of the outward tail current. All values are given as
mean   S.E.M. The differences of the mean values were ana-
lyzed by Student’s t-test and ANOVA for paired data, and a 
P-value of  0.05 was considered significant.
Experimental Solutions
The composition of the modified Tyrode solution was:
137 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 1.0 mM MgCl2,
0.3 mM NaH2PO4, 5.0 mM glucose and 5.0 mM HEPES.
The pH was adjusted to 7.4 with NaOH. The constituents of
Ginkgo biloba extract, ginkgolides A, B and C, and quercetin
(Tokiwa Phytochemical Co., Tokyo, Japan) were dissolved
with DMSO. Bath solutions with the desired concentrations
were made and superfused. The pipette solution (intracellular)
contained: 110 mM K-aspartate, 20 mM KCl, 1 mM MgCl2,
10 mM EGTA, 5 mM Mg-ATP, 5 mM creatine phosphate and
5 mM HEPES (pH 7.2). The pipette solution for the measure-
ment of ICa alone contained: 110 mM CsOH, 20 mM CsCl,
2 mM MgCl2, 10 mM EGTA, 5 mM MgATP, 5 mM creatine
phosphate, 100 mM aspartic acid and 5 mM HEPES (pH 7.2).
Results
Gingko biloba Effects on the Action Potentials
To examine the effects of each constituent on the action
potential configuration, a current-clamp experiment was
carried out. The isolated single cell was stimulated at 1 Hz. As
shown in Fig. 1A, ginkgolide A (at  1   M) markedly
prolonged the APD; at 3  M, 75% and 90% repolarizations of
APD (APD75 and APD90) were by  43.8   3.6% (n   8,
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Figure 1. Modulation of the action potentials by the constituents of Ginkgo
biloba extract in guinea pig ventricular cardiomyocytes. (A) Effects of
ginkgolide A on the action potentials. (B) Action potentials in ginkgolide B.
(C) Action potentials in ginkgolide C. (D) Quercetin on action potentials.
Each constituent from 0.1–3  M was cumulatively added to bath
solution. Horizontal lines indicate 0 mV. Symbols used are control (C) and
washout (W).P   0.001) and by  40.9   4.2% (n   8, P   0.001), respect-
ively (Fig. 2A). Ginkgolide B at low concentrations (0.1–
0.3  M) markedly prolonged APD75 and APD90, but at high
concentrations (1–3  M) it decreased both of the APDs
(although the APDs were still enhanced in comparison with
the control) (Fig. 1B). The APD75 and APD90 at 0.3  M were
 63.6   4.8% (n   9, P   0.001) and  58.3   3.6% (n   6,
P   0.001), respectively, and at 3  M were  16.2   3.9%
(n   9, P   0.05) and  15.0   3.7% (n   9, P   0.05),
respectively (Fig. 2B).
On the other hand, ginkgolide C at low concentrations
(0.3  M) prolonged APD, whereas at high concentrations 
(1–3  M) it markedly shortened APD (Fig. 1C). The APD75
and APD90 at 0.3  M were altered by  15.5   3.7% (n   8,
P   0.05) and  9.9   2.6% (n   8, P   0.05), respectively,
and at 3  M they were altered by  38.5   2.8% (n   8,
P   0.001) and  37.2   3.5% (n   8, P   0.01), respect-
ively (Fig. 2C). Quercetin at 0.1–1  M tended to prolong the
APD, and at 3  M prolonged the APD75 by  11.9   3.4%
(n   8, P   0.05) and APD90 by   17.9   3.0% (n   8,
P   0.05) (Figs 1D and 2D).
The maximum rate of deporization (Vmax) significantly
decreased by ~18–20% (n   8–9) at higher concentrations
(1–3  M) of these constituents. Other action potential parame-
ters were also unaffected in the presence of all the constituents.
The modulation of the action potential configurations by the
constituents is summarized in Fig. 3. A washout of the drugs for
15–20 min recovered to ~70–80% of the control value.
Constituents of Gingko biloba and Quercetin Exert
Contrasting Effects on Ionic Currents
Whole-cell patch voltage-clamp experiments were performed to
examine the effects of the constituents on the underlying ionic
currents. Test pulses (1 s duration) were applied to  20 to
60 mV and  40 to  120 mV from a holding potential of
 30 mV. The average capacitance was 86.1   2.0 pF (n   44).
As shown in Fig. 4, ginkgolide A (1  M) enhanced both the
Ca2  current (ICa), by 68.2   2.8% (n   7, P   0.001), and the
delayed rectifier K  current (IK) by 66.3   3.8% (n   7,
P   0.001). Each constituent (0.1–3  M) was cumulatively
administrated to the bath solution. Ginkgolide B at 0.3  M also
increased the ICa at 10 mV by 58.1   2.8% (n   6, P   0.001)
(Fig. 5). Increasing the concentrations (1–3  M) still enhanced
the ICa, but the maximal response at 0.3  M decreased. The IK
at 60 mV increased by 89.3   3.8% (n   6, P   0.001) at
3  M, but the inwardly rectifying K  current (IK1) was not
affected significantly. Ginkgolide C had a smaller or no effect on
the ICa, but markedly increased the IK by 59.2   2.8% (n   7,
P   0.001) at 3  M (Fig. 6).
On the other hand, the application of quercetin (0.1–3  M)
inhibited the ICa (Fig. 7A and B). The ICa at 10 mV decreased by
34.9   3.2% (n   8, P   0.05) at 0.3  M and by 56.8   3.3%
(n   8, P   0.05) at 3  M. The responses were produced in
a concentration-dependent manner. Simultaneously, the IK at
60 mV increased by 60.4   2.7% (n   8, P   0.001) at 0.3  M
and by 89.7   3.3% (n   8, P   0.001) at 3  M. Quercetin
simultaneously did not affect the IK1 to a significant extent
(by ~10–15%) at low concentrations, but at 3  M inhibited the
IK1 by 12.4   2.1% (n   8, P   0.05). The responses to the
constituents for the ICa and IK currents are summarized in Fig. 8.
The responses to all the constituents were recovered to ~80–90%
of the control value after a 20-min washout.
Discussion
The present experiments showed that: (i) ginkgolide A
prolonged the APD, but ginkgolides B and C shortened APD;
(ii) quercetin prolonged the APD; (iii) the constituents also
inhibited the Vmax and the RP was unaffected; (iv) ginkgolides
A and B increased ICa and IK, and decreased IK1; (v) ginkgolide
C failed to affect the ICa but increased the IK; (vi) quercetin
inhibited ICa, and enhanced IK but decreased IK1; and (vii) these
responses were almost reversible after a washout. These results
indicate that acute administrations of these constituents
can produce the effective actions on cardiomyocytes. Each
constituent never exhibits a uniform response.
In recent clinical and experimental experiments, GBE has
been found to be effective against ischemic brain injury (11,17)
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Figure 2. Changes in the action potential durations (75% and 90%
repolarizations) in the presence of the constituents (0.1–3  M). Maximum
responses at different concentrations of each constituent are plotted. Values are
represented as mean   S.E.M. *P   0.05, **P   0.01, ***P   0.001, with
respect to control value.280 Electropharmacology of constituents of GBE
Figure 3. Summary of the effects on action potential parameters. (A) Ginkgolide A, (B) ginkgolide B, (C) ginkgolide C, (D) quercetin. APA, action potential
amplitude; MDP, maximum diastolic potential; APD75, 75% repolarization of the action potential duration; APD90, 90% repolarization of the action potential
duration; Vmax, maximum rate of depolarization. Values are represented as mean   S.E.M. *P   0.05, **P   0.01, ***P   0.001, with respect to control value.
Figure 4. Modulation by ginkgolide A of the ionic currents. (A) Current traces in control. (B) Current traces in ginkgolide A (3  M). Test pulses for 1 s were
applied to  20 to 60 mV and  40 to  120 mV from a holding potential of  30 mV. Horizontal line before the current traces indicates zero current level.
(C) Current–voltage relationship for Ca2  current. (D) Current–voltage relationship for the delayed rectifier K  current and the inwardly rectifying K  current.
Symbols used are control (open circles), 0.3  M (triangles) and 1  M (squares) of ginkgolide A, and washout (filled circles).and cerebral disorders due to aging (18). The mechanisms
of the beneficial effects of GBE are considered to be
improvements in: (i) hemodynamic disorders (6,7,19); (ii) PAF-
associated abnormalities (3,4,20,21); (iii) cell damage induced
by free radicals (8–10); and (iv) a decrease in ATP level during
anoxia (5). In fact, these effects have recently been recognized
clinically by several double-blind studies with GBE versus
placebo (22–25).
APD Regulation
In experiments for the cardiovascular system, GBE does
not affect heart rate and contractility, but produces a
concentration-dependent increase in coronary flow (12,13). In
our laboratory, however, GBE caused a negative chronotropic
effect in rabbit SA nodal cells (unpublished data). Also, GBE
inhibited ICa and IK, but bilobalide (a constituent) increased
them in guinea pig ventricular cardiomyocytes (14).
Simultaneously, GBE prolonged the APD, whereas bilobalide
shortened it. In the present experiments, a major action of
the constituents was the alteration of APD involved with the
effects on the ionic channels. The APD means a period for the
repolarization of the membrane, making T wave on ECG.
Thus, the APD of cardiac myocytes is clinically reflected
directly to the QT interval. The QT interval is a reflection of
the repolarization of action potential, which is mainly respon-
sible for the modulation of IK. The APD prolongation increases
the refractory period and simultaneously elevates the cellular
Ca2  concentration (26–28). Therefore, the constituents would
play an important role as ionic channel modulators of
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Figure 5. Modulation by ginkgolide B of the ionic currents. (A) Current traces in control. Test pulses for 1 s were applied to  20 to 60 mV and  40 to 
 120 mV from a holding potential of  30 mV. (B) Current traces in ginkgolide B (0.3  M). Test pulses for 1 s were applied to  20 to 60 mV. Holding poten-
tial was  30 mV. (C) Current traces at 3  M. Test pulses for 1 s were applied to  20 to 60 mV and  40 to  120 mV from a holding potential of  30 mV.
Horizontal line before the current traces indicates zero current level. (D) Current–voltage relationship for Ca2  current. (E) Current–voltage relationship for the
delayed rectifier K  current and the inwardly rectifying K  current. Symbols used are control (open circles), 0.1  M (triangles), 0.3  M (squares) and 1  M (filled
circles) of ginkgolide B.282 Electropharmacology of constituents of GBE
Figure 6. Modulation by ginkgolide C of the ionic currents in guinea pig ventricular cardiomyocytes. (A) Current traces in control. (B) Current traces in
ginkgolide C (3  M). Test pulses for 1 s were applied to  20 to 60 mV and  40 to  120 mV from a holding potential of  30 mV. Horizontal line before the
current traces indicates zero current level. (C) Current–voltage relationship for the Ca2  current. (D) Current–voltage relationship for the delayed rectifier K 
current and the inwardly rectifying K  current. Symbols used are control (open circles), 0.3  M (triangles) and 3  M (squares) of ginkgolide C.
Figure 7. Modulation by quercetin of the ionic currents in guinea pig ventricular cardiomyocytes. (A) Current traces in control. (B) Current traces in quercetin
(3  M). Test pulses for 1 s were applied to  20 to 60 mV and  40 to  120 mV. Holding potential was  30 mV. Horizontal line before the current traces indic-
ates zero current level. (C) Current–voltage relationship for Ca2  current. (D) Current–voltage relationship for the delayed rectifier K  current and the inwardly
rectifying K  current. Symbols used are control (open circles), 0.3  M (triangles) and 3  M (squares) of quercetin.cadiomyocytes, although the effects of each constituent on the
APD and the ionic currents were not exhibited in a uniform
direction. Quercetin, a kind of flavonoid, had a smaller or no
effect on the action potentials, but caused the APD prolonga-
tion only at high concentrations. Also, quercetin inhibited ICa
and enhanced IK. Quercetin has been reported to possess
many pharmacological effects (29,30); the modification of
eicosanoid synthesis, prevention of platelet aggregation, and
vasorelaxation due to the inhibition of PK-C.
Modulation of the Ionic Currents
Furthermore, these constituents also acted on the Vmax,
although they did not affect other action potential parameters.
In general, the Vmax is used as an activator of the Na  channel
current (INa). Thus, the constituents have an inhibitory action
on the INa, resulting in an inhibition of the conduction velocity
and a suppression of excitability. In addition, the constituents
simultaneously modulated the ionic channel currents such as
ICa,I K,I K1 and INa. These effects might cause antiarrhythmic
actions. In all the constituents, IK enhancement was finally
produced, indicative of a cell protection due to an APD
shortening and a decline of cellular Ca2  concentration.
The channel activity of single myocytes might be caused a
run-down, especially Ca2  channel and rapidly activating K 
channel. The cells not causing run-down were chosen and used
for the experiments. However, there may be a limitation to
patch-clamp experiments. The responses to the constituents
were considered to be due to the effects of constituents, because
of the reversible response. Therefore, these constituents would
exert many helpful and protective actions upon cardiac cells.
Clinical Uses and Summary
GBE can be administered to patients with mild to moderate
symptoms of cerebral insufficiency (1,2). The half-life of GBE
is 2–3 h (11). In pharmacokinetic analysis, the bioavailabilities
of ginkgolides A and B are practically high, but that of
ginkgolide C is very low (31). Of the GBE-containing
flavonoids, quercetin has the highest percentage (8.91%).
With regard to the distribution of radioactivity in the cardio-
vascular system, the tissues in areas such as vein, heart and
aorta are relatively higher 3–7 h after oral administration (32).
Quercetin possesses a vasodilating action (33,34). Also, the
histamine-induced contraction of isolated guinea pig intestine
was inhibited by a mixture of flavonoids (35). In our labora-
tory, GBE as a mixture exhibited a potent vasodilatory action
(34). Therefore, these responses are most likely produced by
the modulation of ionic channel currents that have been
demonstrated in this study.
It has been reported that a single dose of GBE does not pro-
duce potent pharmacological activities, and repeated doses are
needed to produce beneficial effects over a long period of
administration (36–38). In the present in vitro experiments,
however, acutely single administrations produced marked
actions on the ionic channel currents and the action potentials.
Since GBE is a mixture of its constituents, the total response
to GBE would be a result of complex interactions with the con-
stituents. Therefore, the constituents from GBE would play an
important role in modulating the strong APD prolongation by
interacting with each other. Although relatively higher concen-
trations were used in this study, because the pharmacological
effects on the ionic channels were so remarkable, GBE and its
constituents would be helpful in the treatment of cerebral dis-
orders due to their effects on central nervous system (CNS)
neurons. Further experiments are needed to elucidate the
detailed mechanisms of the cardiac actions of Ginkgo biloba.
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